Overview

* Fulgent Q3 revenue grows 17% yr/yr, beating analyst expectations

* Company raises full-year 2025 revenue guidance to $325 mln

* Non-GAAP income for Q3 at $4.5 mln, despite GAAP loss

Outlook

* Fulgent raises full-year 2025 revenue guidance to $325 mln

* Company expects full-year 2025 GAAP loss of $1.70 per share

* Fulgent anticipates $800 mln in cash and investments by year-end

Result Drivers

* LAB SERVICES GROWTH - Co cites strong momentum in its laboratory services business as a key driver of Q3 revenue growth

* THERAPEUTIC DEVELOPMENT - Progress in clinical trials, especially for FID-007, contributed to results, per CEO Ming Hsieh

* GUIDANCE RAISED - Co raises full-year 2025 revenue and EPS guidance, reflecting confidence in strategic execution, per CFO Paul Kim

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $84.07 $81.40

Revenue mln mln (3

Analysts

)

Q3 EPS -$0.21

Q3 Beat $700,000 -$6.05

Adjusted mln (3

EBITDA Analysts

)

Q3 Miss -$7.51 -$7.24

Pretax mln mln (2

Profit Analysts

)

Q3 Gross $35.51

Profit mln

Q3 $50.86

Operatin mln

g

Expenses

Q3 -$15.35

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the healthcare facilities & services peer group is "buy"

* Wall Street's median 12-month price target for Fulgent Genetics Inc ( FLGT ) is $25.00, about 10.8% above its November 6 closing price of $22.31

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)